Welcome to EBE, the Voice of Biopharmaceuticals in Europe

All stakeholders should stand to benefit from the advances in healthcare that biopharmaceutical technology offers and they all have a role to play. EBE has become a key focal point for information exchange between the research-based biopharmaceutical industry operating in Europe and all major stakeholders engaged in this process.

Biotechnology is delivering significant advances in human healthcare. Entirely new medicines are being created, notably for rare or previously untreated diseases. Biotech production methods provide safer versions of existing treatments in unlimited quantities. Biotechnology has revolutionised the research and development of new medicines and allows better product targeting for specific diseases and patient groups. A greater understanding of the genetic causes of disease allows early detection and treatment, and the new field of gene therapy may even herald the possibility to cure diseases, not simply treat them.

Current Issues

EBE - BIO Deutschland Business Development Conference

Energizing Partnerships within the European Biotechnology Industry

European Biopharmaceutical Enterprises (EBE) and BIO Deutschland are pleased to invite you to attend their European Business Development Conference on “Energizing Partnerships within the European Biotechnology Industry”, which will take place in Munich on 5-6 June 2008. Our conference will provide you with an exclusive platform to learn, network and discuss collaboration opportunities. The registration desk is now open, so have a look at the programme and register without delay.

more

BIO-Europe Spring 2008

The EBE supported BIO Europe Spring 2008,  which took place in Madrid on 7-9 April and was a very successful partnering event. EBE had invited biopharmaceutical companies around Europe to send business development teams to attend this major biotech business conference. BIO Europe Spring is the new spring equivalent of the BIO Europe meeting held annually in Germany in the autumn and for which EBE is leading partner.

more

Public Consultation Rare Diseases - EBE/EuropaBio joint input

EC Consultation on “Rare Diseases - Europe’s Challenges”: Joint EBE /EuropaBio’s Response to DG Sanco

The industry, through a joint task force of the European Biopharmaceutical Enterprises (EBE) and European Association of Bio-Industries (EuropaBio), welcomed the initiative of the European Commission (DG SANCO) to conduct a public consultation on rare diseases, which concluded on 14 February 2008. 

more

Launch of Innovative Medicines Initiative - IMI Information Day, 30 April, Brussels

A major Information Day is going to be held in Brussels on 30 April to present opportunities for submitting proposals under the new Innovative Medicines Initiative (IMI). This event will provide a brief overview of the IMI concept and its potential impact, an overview of the first Call for Proposals as well as information about the proposal submission and evaluation procedures.

more
  • Members Login
  • Join EBEclick here for more information